Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.50M | 3.55M | 19.65M | 35.47M | 181.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.50M | 3.55M | 19.65M | 35.47M | 181.74M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.50M | 3.55M | 19.65M | 35.47M | 181.74M |
| SG&A Expenses | 125.10M | 121.77M | 118.45M | 116.19M | 111.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 628.45M | 604.63M | 566.86M | 509.24M | 481.15M |
| Operating Income | -625.95M | -601.08M | -547.21M | -473.77M | -299.41M |
| Income Before Tax | -648.89M | -612.46M | -548.65M | -478.06M | -303.39M |
| Income Tax Expenses | 649.00K | -2.77M | -1.29M | -546.00K | -546.00K |
| Earnings from Continuing Operations | -649.54 | -609.69 | -547.36 | -477.51 | -302.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.82M | 10.20M | 8.73M | 6.72M | 6.03M |
| Net Income | -639.71M | -599.49M | -538.64M | -470.79M | -296.81M |
| EBIT | -625.95M | -601.08M | -547.21M | -473.77M | -299.41M |
| EBITDA | -606.38M | -582.49M | -529.78M | -457.85M | -285.35M |
| EPS Basic | -5.15 | -5.00 | -4.65 | -4.24 | -2.77 |
| Normalized Basic EPS | -3.19 | -3.11 | -2.89 | -2.63 | -1.71 |
| EPS Diluted | -5.16 | -5.01 | -4.66 | -4.25 | -2.78 |
| Normalized Diluted EPS | -3.19 | -3.11 | -2.89 | -2.63 | -1.71 |
| Average Basic Shares Outstanding | 496.69M | 479.26M | 462.11M | 444.91M | 428.39M |
| Average Diluted Shares Outstanding | 496.69M | 479.26M | 462.11M | 444.91M | 429.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
